Scribe Therapeutics priced a roughly $129 million IPO, bringing a CRISPR-focused in vivo platform targeting cardiovascular and metabolic disease onto the Nasdaq under the ticker SCTX. The company sold 8.6 million shares at $15, following an upsized offering that pushed gross proceeds higher and drew strong first-day trading enthusiasm. Scribe’s lead program, STX-1150, is designed to silence PCSK9, with a Phase 1 study recently launched in Australia. Additional early efforts include APOC3- and LPA-targeting programs, which the company said would be funded alongside ongoing clinical execution. The deal adds to a revived IPO pipeline for genetic medicines, signaling renewed appetite for genome-editing risk—particularly where candidates target established cardiometabolic biology.